Zealand Pharma A/S ZLDPF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -47.83% | 17,482.13% | 15,363.79% | 12,415.77% | 2,483.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -47.83% | 17,482.13% | 15,363.79% | 12,415.77% | 2,483.23% |
| Cost of Revenue | 100.00% | -100.00% | -100.00% | -97.89% | -120.43% |
| Gross Profit | -47.87% | 18,535.27% | 17,546.16% | 16,545.76% | 2,721.14% |
| SG&A Expenses | 17.05% | 25.04% | 29.09% | 82.17% | 71.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -100.00% | 757.77% | -- | 385,915.58% | 13,982.86% |
| Total Operating Expenses | 29.21% | 79.63% | 81.03% | 79.66% | 78.92% |
| Operating Income | -67.57% | 602.72% | 672.18% | 768.12% | 1,157.82% |
| Income Before Tax | -60.11% | 714.92% | 778.49% | 807.49% | 1,166.99% |
| Income Tax Expenses | -80.98% | 13,629.87% | 12,484.39% | 13,102.25% | 12,385.92% |
| Earnings from Continuing Operations | -58.45% | 668.25% | 728.23% | 753.51% | 1,094.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.45% | 668.25% | 728.23% | 753.51% | 1,094.90% |
| EBIT | -67.57% | 602.72% | 672.18% | 768.12% | 1,157.82% |
| EBITDA | -67.25% | 612.21% | 684.22% | 783.17% | 1,189.90% |
| EPS Basic | -58.21% | 650.11% | 688.78% | 682.98% | 960.13% |
| Normalized Basic EPS | -60.86% | 661.26% | 700.93% | 711.69% | 1,005.68% |
| EPS Diluted | -57.92% | 641.04% | 679.21% | 673.69% | 943.79% |
| Normalized Diluted EPS | -60.59% | 652.07% | 691.17% | 702.03% | 988.70% |
| Average Basic Shares Outstanding | -0.42% | 2.63% | 6.15% | 11.48% | 17.31% |
| Average Diluted Shares Outstanding | -0.62% | 2.99% | 6.52% | 11.87% | 16.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |